KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Deferred Revenue (2016 - 2019)

NovoCure's Current Deferred Revenue history spans 5 years, with the latest figure at $19.6 million for Q4 2019.

  • For Q4 2019, Current Deferred Revenue rose 4.32% year-over-year to $19.6 million; the TTM value through Dec 2019 reached $19.6 million, up 4.32%, while the annual FY2019 figure was $19.6 million, 4.32% up from the prior year.
  • Current Deferred Revenue for Q4 2019 was $19.6 million at NovoCure, up from $18.8 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $19.6 million in Q4 2019 and bottomed at $52000.0 in Q4 2015.
  • The 5-year median for Current Deferred Revenue is $5.0 million (2017), against an average of $9.1 million.
  • The largest annual shift saw Current Deferred Revenue soared 4259.62% in 2016 before it grew 4.32% in 2019.
  • A 5-year view of Current Deferred Revenue shows it stood at $52000.0 in 2015, then skyrocketed by 4259.62% to $2.3 million in 2016, then soared by 118.75% to $5.0 million in 2017, then skyrocketed by 278.48% to $18.8 million in 2018, then rose by 4.32% to $19.6 million in 2019.
  • Per Business Quant, the three most recent readings for NVCR's Current Deferred Revenue are $19.6 million (Q4 2019), $18.8 million (Q4 2018), and $5.0 million (Q4 2017).